Caren van Roekel

158 Chapter 5 26. Prince JF,vandenBoschM,Nijsen JFW,Smits MLJ, van den Hoven AF, Nikolakopoulos S, et al. Efficacy of radioembolization with holmium-166 microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med. 2017. 27. Kosmider S, Tan TH, Yip D, Dowling R , Lichtens tein M, Gibbs P. Radioembolization in combination with systemic chemotherapy as first- line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol. 2011;22(6):780-6. 28. Ahmadzadehfar H, Sabet A, Meyer C, Habibi E, Biersack HJ, Ezziddin S. The Importance of Tc-MAA SPECT/CT for Therapy Planning of Radioembolization in a Patient Treated With Bevacizumab. Clin Nucl Med. 2012;37:1129-30. 29. Lam MG, Banerjee S, Louie JD, Abdelmaksoud MH, Iagaru AH, Ennen RE, et al. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovasc Interv Radiol. 2013;36(6):1536-47. 30. Bhooshan N, Sharma NK, Badiyan S, Kaiser A, Moeslein FM, Kwok Y, et al. Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres. J Gastrointest Oncol. 2016;7(6):931-7. 31. Jakobs TF, Paprottka KJ, Raessler F, Strobl F, Lehner S, Ilhan H, et al. Robust evidence for long-term survival with (90) Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. Eur Radiol. 2017;27(1):113-9. 32. Sato K, Lewandowski R, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable Chemorefractory Liver Metastases: Radioembolization with 90Y Microspheres—Safety, Efficacy, and Survival. Radiology. 2008;247(2):507-15. 33. Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, et al. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorect Cancer. 2015;14(3):146-53. 34. SalemR, Thurston KG. Radioembolization with 90Yttrium microspheres: a state- of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251-78. 35. SalemR, Thurston KG. Radioembolization with 90yttrium microspheres: a state- of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol. 2006;17(9):1425-39. 36. SalemR, Thurston KG. Radioembolization with yttrium-90 microspheres: a state- of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17(10):1571-93. 37. Smits MLJ, Nijsen JFW, van den Bosch MAAJ, Lam MGEH, Vente MAD, Mali WPTM, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13(10):1025-34.